Últimas noticias sobre Shineco (NASDAQ:SISI) Bolsa

Shineco

Shineco Inc aims to care for a healthy life and improve the quality of life by providing safe, efficient, and high-quality health products and services to society. The company has researched and developed various vitro diagnostic reagents and related medical devices to date, and it also produces and sells healthy and nutritious food.

Shineco Inc

On Friday, Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) stock plunged after the company released headline results from the REDEFINE 1 Phase 3 trial in the <a href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=915082" target="_blank" rel="noreferrer noopener">global REDEFINE program</a>.
REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to the individual components cagrilintide 2.4 mg, semaglutide 2.4 mg, and placebo, all administered once-weekly.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42467660/novo-nordisks-ozempic-label-expansion-snags-approval-from-european-drug-regulators-advisory-panel" rel="noreferrer noopener">Novo Nordisk&#8217;s Ozempic Label Expansion Snags Approval From European Drug Regulator&#8217;s Advisory Panel</a>
The <a target="_blank" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=915082" rel="noreferrer noopener">trial</a> included 3,417 randomized people with obesity or overweight with one or more comorbidities and a mean baseline body weight of 106.9 kg.
The trial achieved its primary endpoint by demonstrating a statistically significant and superior weight loss with CagriSema versus placebo at week 68.
When evaluating the effects of treatment if all people adhered to treatment, people treated with CagriSema achieved a weight loss of 22.7% after 68 weeks compared to a reduction of 11.8% with cagrilintide 2.4 mg, 16.1% with semaglutide 2.4 mg and 2.3% with placebo alone.
In November, Novo Nordisk said its hybrid drug, CagriSema, aims to reduce weight by 25% without <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41706292/as-race-to-best-miracle-obesity-drug-heats-up-ozempic-maker-novo-nordisk-tests-new-hybrid-drug-th" rel="noreferrer noopener">added side effects</a>.
In addition, 40.4% of patients who received CagriSema reached a weight loss of 25% or more after 68 weeks, compared to 6.0% with cagrilintide 2.4 mg, 16.2% with semaglutide 2.4 mg, and 0.9% with placebo.
When applying the treatment policy estimand, people treated with CagriSema achieved a weight loss of 20.4% compared to a reduction of 11.5% with cagrilintide 2.4 mg, 14.9% with semaglutide 2.4 mg and 3.0% with placebo.
In the trial, CagriSema, cagrilintide 2.4 mg and semaglutide 2.4 mg appeared to have a safe and well-tolerated profile. The most common adverse events with CagriSema were gastrointestinal, and the vast majority were mild to moderate and diminished over time, consistent with the GLP-1 receptor agonist class.
The results from the second pivotal phase 3 trial, REDEFINE 2, in adults with type 2 diabetes and either obesity or overweight are expected during the first half of 2025.
In reaction to lower-than-expected trial data, Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) stock is trading higher. Lilly&#8217;s own obesity injection containing tirzepatide demonstrated sustained average weight loss of 22.9% (15 mg dose) through the three-year treatment <a target="_blank" href="https://www.benzinga.com/24/11/41985752/eli-lillys-detailed-phase-3-trial-data-show-99-of-patients-on-popular-mounjarozepbound-remained-diabetes-free-for-even-at-three-years" rel="noreferrer noopener">period for the efficacy estimandi</a>.&nbsp;
Recently, Novo Nordisk stock came under pressure when two new studies from the University of Southern Denmark suggested that Ozempic, a diabetes medication, may increase the risk of developing a <a target="_blank" href="https://www.benzinga.com/24/12/42557565/ozempic-maker-novo-nordisks-poised-to-go-under-european-review-for-potential-increased-risk-of-rare-eye-disease" rel="noreferrer noopener">rare eye condition</a>.
Price Action: NVO stock is down 16.50% at $86.33, and LLY stock is up 8.91% at $825 during the premarket session at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/12/42600472/your-healthcare-costs-are-soaring-us-spending-reached-5-trillion-in-2023-with-major-increase-in-obesity-and-diabetes-drugs-hospital-services" target="_blank" rel="noreferrer noopener">Your Healthcare Costs are Soaring! US Spending Reached $5 Trillion In 2023 with Major Increase in Obesity and Diabetes Drugs, Hospital Services</a></li>
</ul>
Photo via Shutterstock

Biotech

Large Cap

News

Health Care

Movers

Trading Ideas

General

Novo Nordisk's Hybrid Weight Loss Drug Falls Short On Expectations, Stock Plunges

IIPR

Innovative Industrial Properties Reports Default By Pharmacann On Its Obligations To Pay Rent For The Month Of December Under Six Of The Eleven Leases, For Properties Located In Illinois, Massachusetts, Michigan, New York, Ohio And Pennsylvania

Keefe, Bruyette &amp; Woods analyst Aidan Hall upgrades Evercore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVR#NYSE">EVR</a>) from Market Perform to Outperform and raises the price target from $269 to $339.

Upgrades

Price Target

Analyst Ratings

Keefe, Bruyette & Woods Upgrades Evercore to Outperform, Raises Price Target to $339

Needham analyst Tom Nikic reiterates Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) with a Buy and maintains $84 price target.

Reiteration

Needham Reiterates Buy on Nike, Maintains $84 Price Target

Keefe, Bruyette &amp; Woods analyst Aidan Hall downgrades Lazard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAZ#NYSE">LAZ</a>) from Outperform to Market Perform and lowers the price target from $65 to $57.

Downgrades

Keefe, Bruyette & Woods Downgrades Lazard to Market Perform, Lowers Price Target to $57

Needham analyst Chris Pierce maintains CarMax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMX#NYSE">KMX</a>) with a Buy and raises the price target from $90 to $98.

Needham Maintains Buy on CarMax, Raises Price Target to $98

As 2025 approaches, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) finds itself navigating a shifting macroeconomic landscape, with fading tailwinds raising <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42550405/trump-inauguration-could-coincide-with-a-harrowing-dump-for-crypto-arthur-hayes-warns">concerns about sustained momentum</a>, according to a report.
What Happened: The <a href="https://www.benzinga.com/24/12/42610958/expecting-up-to-four-fed-rate-cuts-in-2025-says-this-analyst-despite-hawkish-powell-saying-it-was-close-on-the-decision-to-cut-or-not-heres-why">Federal Reserve&#8217;s hawkish stance</a>, coupled with broader macroeconomic headwinds, suggests a year of heightened caution for traders and investors, 10x Research report on Friday stated.
&#8220;Some indicators we monitor suggest that the air is getting thinner,&#8221; the report cautioned. 
This sentiment now looms larger, with Bitcoin's recent failed wedge breakout putting its bullish momentum in jeopardy. 
Traders are advised to remain vigilant as these technical signals highlight increased risks for the cryptocurrency. 
The situation highlights a broader narrative: Bitcoin&#8217;s ability to maintain its support level depends on external factors that may no longer be favorable.
One of the more striking concerns is the diminishing impact of MicroStrategy's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42561551/microstrategy-chairman-michael-saylor-eyes-intelligent-leverage-with-bitcoin-purchases">aggressive Bitcoin accumulation</a>.
The company has spent $16 billion acquiring approximately 159,000 BTC since November.
While this announcement initially sparked optimism, Bitcoin&#8217;s price appreciation has been modest, and MicroStrategy's share price has largely stagnated. 
&#8220;Despite the massive $16 billion purchase, Bitcoin's price gain of roughly 10% during this period raises questions about the broader market's strength,&#8221; the report notes. 
This disparity suggests that even significant bullish catalysts might no longer be enough to drive the market higher.
Monetary policy also casts a long shadow over Bitcoin's 2025 outlook. 
The Federal Reserve's decision to remove its commitment to rate hikes in late January 2024 initially led to a strong rally. 
However, the lack of a clear timeline for rate cuts resulted in a six-month consolidation phase. 
Although Bitcoin experienced another rally in September following the Fed&#8217;s first rate cut, the central bank's December meeting reintroduced uncertainty.
Analysts point out that the Fed is unlikely to take a dovish stance in early 2025, which could keep Bitcoin in a lackluster trading range.
Inflation data further complicates the picture. Despite the Federal Reserve's efforts, progress on reducing inflation has been minimal. Bond yields remain elevated, with 2-year Treasury yields at 4.3%. 
This persistence creates tighter liquidity conditions, offsetting Treasury measures aimed at lowering refinancing rates. 
The Treasury refunding announcement on Feb. 5 next year is expected to provide critical insights into how U.S. debt strategies may evolve under the new administration.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42599660/bitfinex-hacker-of-biggest-heist-ever-documentary-takes-responsibilitybut-his-wife-has-other-ideas">Bitfinex Hacker Of &#8216;Biggest Heist Ever&#8217; Documentary Takes Responsibility—But His Wife Has Other Ideas</a>
What&#8217;s Next: The incoming Treasury Secretary's potential reversal of short-term debt reliance could introduce additional volatility, raising further concerns for Bitcoin traders.
Market participants are also closely watching inflation reports scheduled for Jan. 15, Feb. 12, and beyond. 
These data points will play a significant role in shaping expectations around Federal Reserve policy, which is seen as a key driver of Bitcoin's performance. 
The report highlights the importance of these external forces, noting that Bitcoin's fate is increasingly <a href="https://www.benzinga.com/markets/cryptocurrency/24/01/36720396/is-bitcoin-a-safe-hedge-against-inflation">tied to macroeconomic trend</a>s.
"While we do not want to turn too bearish, it's clear the tailwinds supporting the market may be fading," the report concludes. 
Analysts are cautious but not dismissive of Bitcoin's resilience, emphasizing that while it remains above $95,000, the risk of heightened volatility and prolonged consolidation persists.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42597209/sonic-and-injective-pioneer-cross-chain-ai-agent-platform">Sonic And Injective Pioneer Cross-Chain AI Agent Platform</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

MSTR

Bitcoin's 2025 Outlook Suddenly Looks Uncertain: Here's Why

Raymond James analyst Steve Moss upgrades Brookline Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKL#NASDAQ">BRKL</a>) from Market Perform to Strong Buy and announces $16 price target.

BRKL

Raymond James Upgrades Brookline Bancorp to Strong Buy, Announces $16 Price Target

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintains Personalis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>) with a Buy and raises the price target from $9 to $11.

PSNL

HC Wainwright & Co. Maintains Buy on Personalis, Raises Price Target to $11

Merck Disclosed Closing Of Exclusive Global License Agreement For LM-299, A Novel Investigational PD-1/VEGF Bispecific Antibody From LaNova Medicine; Company To Record Pre-tax Charge Relating To Upfront Payment Of $588M, Or $0.18 Per Share, In Q4 2024 GAAP And Non-GAAP Results

Raymond James analyst Steve Moss upgrades Camden National (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAC#NASDAQ">CAC</a>) from Market Perform to Outperform and announces $50 price target.

Raymond James Upgrades Camden National to Outperform, Announces $50 Price Target

HC Wainwright &amp; Co. analyst Vernon Bernardino reiterates Humacyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) with a Buy and raises the price target from $12 to $15.

HUMA

HC Wainwright & Co. Reiterates Buy on Humacyte, Raises Price Target to $15

Chardan Capital analyst Rudy Li initiates coverage on Stoke Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STOK#NASDAQ">STOK</a>) with a Buy rating and announces Price Target of $24.

Initiation

STOK

Chardan Capital Initiates Coverage On Stoke Therapeutics with Buy Rating, Announces Price Target of $24

Trump Media &amp; Technology Group Corp&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) experienced a notable decline in its stock value. The company&#8217;s shares fell by 5.31% during pre-market trading on Friday, coinciding with a major decision by&nbsp;Donald Trump.
What Happened: Trump Media &amp; Technology Group Corp saw its shares fall by 5.31% <a href="https://www.benzinga.com/markets/equities/24/12/42609228/trump-transfers-entire-djt-stake-to-revocable-trust-ahead-of-inauguration">during pre-market trading</a> on Friday. according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. This decline follows Donald Trump&#8216;s decision to transfer his entire stake in the company to his revocable trust.
The transfer involved 114,750,000 shares, which equates to about 53% of the company&#8217;s ownership. The transaction was completed on Tuesday, with Trump named as the sole beneficiary, as per&nbsp;Securities and Exchange Commission filings&nbsp;released on Thursday.
The shares were transferred to the&nbsp;Donald J. Trump Revocable Trust&nbsp;without any monetary exchange. This move comes shortly after Trump participated in ringing&nbsp;the opening bell at the&nbsp;New York Stock Exchange, where&nbsp;DJT&#8217;s stock has more than doubled in value this year.
See Also:&nbsp;<a href="https://www.benzinga.com/trading-ideas/movers/24/12/42567762/bitcoin-ethereum-dogecoin-fall-after-fed-shows-no-interest-for-piling-btc-top-analyst-says-sentiment-shifting-2025-suddenly-looks-a-lot-less-rosy?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Bitcoin, Ethereum, Dogecoin Fall After Fed Shows No Interest For Piling BTC: Top Analyst Says Sentiment Shifting — &#8216;2025 Suddenly Looks A Lot Less Rosy&#8217;</a>
On Tuesday, the company&#8217;s shares closed at $35.41, putting the value of Trump&#8217;s transferred stake at roughly $4 billion. This transfer follows Trump&#8217;s earlier promise in September&nbsp;not to sell his shares&nbsp;in the Truth Social parent&nbsp;company. At that time, he had criticized Nasdaq for routine trading halts and suggested a possible move to the NYSE.
Why It Matters: The transfer of&nbsp;Trump&#8217;s&nbsp;stake in&nbsp;Trump Media &amp; Technology Group Corp&nbsp;comes at a time when the company has seen significant growth. Earlier this year, DJT&#8217;s stock value had more than doubled, reflecting investor confidence in the company&#8217;s potential. However, Trump&#8217;s decision to transfer his shares to a revocable trust raises questions about his future involvement in the company.
In September, Trump had publicly criticized Nasdaq for its trading halts, hinting at a potential shift to the New York Stock Exchange. This move was seen as a strategic effort to align with a more stable trading environment. The recent transfer of shares to the trust could be part of a broader strategy to manage his assets while maintaining influence over the company.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42550405/trump-inauguration-could-coincide-with-a-harrowing-dump-for-crypto-arthur-hayes-warns?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump Inauguration Could Coincide With A &#8216;Harrowing Dump&#8217; For Crypto, Arthur Hayes Warns</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Flickr

Equities

Pre-Market Outlook

Markets

DJT Stock Plummets Over 5% Following Trump's Stake Transfer: Here's More

Sidus Space, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIDU#NASDAQ">SIDU</a>) shares are trading <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">lower in the premarket session on Friday.</a>
The company revealed it had successfully closed a transaction with accredited and institutional investors, issuing units consisting of shares of Class A common stock (or Pre-funded Warrants in lieu) <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42603702/sidus-space-announces-closing-of-14-million-private-placement" rel="noreferrer noopener">along with Common Warrants.</a>
The offering raised approximately $14.1 million in gross proceeds, before deducting fees and expenses.
The company issued 6.82 million shares of Class A common stock (or Pre-funded Warrants) and accompanying Common Warrants, allowing investors to purchase an additional 3.41 million shares at an exercise price of $2.25 per share over the next five and a half years. Each Pre-funded Warrant has an exercise price of $0.0001 per share.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42611748/us-stocks-to-open-lower-as-traders-brace-for-triple-witching-hour-analyst-says-end-of-the-year-recovery-would-not-surprise-anyone" rel="noreferrer noopener">US Stocks To Open Lower As Traders Brace For &#8216;Triple Witching&#8217; Hour: Analyst Says End Of The Year Recovery &#8216;Would Not Surprise Anyone&#8217;</a>
Sidus plans to use the proceeds from this offering for working capital and general corporate purposes. ThinkEquity served as the exclusive placement agent for the transaction.
In November, Sidus Space provided an update <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42188959/sidus-space-announces-lizziesat-2-ready-for-launch" rel="noreferrer noopener">on the progress of its LizzieSat-2 satellite.</a>
The satellite has completed launch processing at the Astrotech Space Operations facility at Vandenberg Space Force Base, California, and has been handed over to SpaceX for the upcoming Bandwagon-2 rideshare mission, scheduled for December 2024.
LizzieSat-2, developed at Sidus Space&#8217;s Florida facility, features advanced sensors such as AIS, multi-spectral methane detection, and high-resolution visual spectrum sensors, alongside the HEO Holmes Imager, developed by HEO (USA), a subsidiary of Australia-based HEO.
Price Action: SIDU shares are trading lower by 7.10% to $4.58 premarket at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42610958/expecting-up-to-four-fed-rate-cuts-in-2025-says-this-analyst-despite-hawkish-powell-saying-it-was-close-on-the-decision-to-cut-or-not-heres-why" target="_blank" rel="noreferrer noopener">Hawkish Powell Aside, This Analyst Expects 4 Fed Rate Cuts In 2025: Here's Why</a></li>
</ul>

Offerings

SIDU

Sidus Space Closes $14.1 Million Capital Raise: Details

HC Wainwright &amp; Co. analyst Andrew Fein initiates coverage on Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) with a Buy rating and announces Price Target of $72.

HC Wainwright & Co. Initiates Coverage On Avidity Biosciences with Buy Rating, Announces Price Target of $72

The collaboration aims to evaluate Eye-Net's cutting-edge cellular vehicle-to-everything (C-V2X) technology as a key component in advanced driver assistance systems, potentially setting a new standard for road safety.

FRSX

Foresight Autonomous Says That Its Wholly Owned Subsidiary Eye-net Mobile Inked Multi-phase Agreement With Softbank Corp. And A Leading Japanese Vehicle Manufacturer

Evercore ISI Group analyst Josh Schimmer downgrades Spero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRO#NASDAQ">SPRO</a>) from Outperform to In-Line and maintains the price target from $5 to $5.

SPRO

Evercore ISI Group Downgrades Spero Therapeutics to In-Line, Maintains Price Target to $5

Telsey Advisory Group analyst Joseph Feldman maintains Dollar Tree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLTR#NASDAQ">DLTR</a>) with a Market Perform and maintains $75 price target.

DLTR

Telsey Advisory Group Maintains Market Perform on Dollar Tree, Maintains $75 Price Target

Following a sluggish session on Thursday and a fall on Wednesday after the Fed&#8217;s <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42563299/feds-powell-shocks-markets-its-a-new-phase-were-significantly-closer-to-neutral">hawkish</a> rate cut, Wall Street is now bracing for Friday&#8217;s &#8220;Triple Witching&#8221; session which is slated to see about $6.6 trillion options to expire.
What Happened: The &#8220;Triple Witching&#8221; hour is a quarterly event that occurs during the final hour of trade on the third Friday of March, June, September, and December. During this period, contracts for stock index futures, stock index options, and stock options all expire at the same time.
According to the Singapore-based broker, uSMART, Friday, Dec. 20 marks the notorious &#8216;Triple Witching&#8217; day, when the total options contracts worth $5.2 trillion on the S&amp;P 500 index, $710 billion worth of contracts on single stocks and $735 billion worth of contracts on the Nasdaq 100, Russell 200 and others are set to expire.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&#x1f4a1;This Friday&#39;s &quot;Triple Witching Day&quot; is expected to be the largest options expiration day in history, with a total of over $6 trillion in options tied to stocks, exchange-traded funds (ETFs), and indices set to expire. <a href="https://twitter.com/hashtag/stocks?src=hash&amp;ref_src=twsrc%5Etfw">#stocks</a> <a href="https://twitter.com/hashtag/ETFs?src=hash&amp;ref_src=twsrc%5Etfw">#ETFs</a> <a href="https://t.co/ExaqHgfzX5">pic.twitter.com/ExaqHgfzX5</a>
&mdash; uSMART (@usmartsg) <a href="https://twitter.com/usmartsg/status/1870010390471684367?ref_src=twsrc%5Etfw">December 20, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The total $6.6 trillion worth of option contracts can be further divided into four categories. Here&#8217;s what they include:
<ul>
<li>About $4.5 trillion notional worth of index options contracts.</li>
<li>$685 billion notional worth of options on futures.</li>
<li>$745 billion notional worth of options on exchange-traded funds.</li>
<li>$710 billion notional worth of contracts on single stocks.</li>
</ul>
&#8220;The timing of buying the dip is complicated by options expiration tomorrow and Christmas next week, but a recovery by the end of the year would not surprise anyone,&#8221; said Louis Navellier, founder of Navellier &amp; Associates.
See Also: <a href="https://www.benzinga.com/24/12/42610441/nikes-new-ceo-says-we-lost-our-obsession-with-sport-as-he-rebukes-old-strategies-on-performance-marketing-isolation-of-wholesalers-aims-to-create-demand">Nike&#8217;s New CEO Blames Promotions For Declining Profits, Says Turnaround Efforts May Hurt As Company Moves To Clear Excess Inventory</a>
Why It Matters: This &#8220;Triple Witching&#8221; convergence can lead to heightened market volatility as traders close, roll over, or offset their expiring contracts, often resulting in unusual price movements and increased trading volumes.
Looking back at the last few triple-witching events, the S&amp;P 500, tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), has struggled during these high-stakes trading days.
<ul>
<li>Sept. 20, 2024: Decline of 0.2%.</li>
<li>Jun. 21, 2024: Decline of 0.5%.</li>
<li>Mar. 15, 2024: Decline of 1%.</li>
<li>Dec. 15, 2023: Decline of 0.6%.</li>
</ul>
Tech stocks, represented by the Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), fell in the last three triple-witching occasions, dropping 0.19% in September, 0.8% in June and 1.2% in March, while surging 0.5% in December 2023.
Price Action: U.S. stock futures declined, ahead of the &#8216;Triple Witching&#8217; Friday. All four major indices were trading lower.
In premarket trading, the SPDR S&amp;P 500 ETF Trust was down 1.05% to $579.97 and the Invesco QQQ Trust ETF fell 1.26% to $507.68, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-1.20%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.75%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.59%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-1.24%</td>
</tr>
</tbody>
</table>
</figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42610958/expecting-up-to-four-fed-rate-cuts-in-2025-says-this-analyst-despite-hawkish-powell-saying-it-was-close-on-the-decision-to-cut-or-not-heres-why">Hawkish Powell Aside, This Analyst Expects 4 Fed Rate Cuts In 2025: Here&#8217;s Why</a></li>
</ul>
Photo courtesy: Shutterstock

Futures

Options

The $6.6 Trillion Question: Can Markets Weather Triple Witching And Hawkish Fed Signals? Here's What This Analyst Says

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth keeping an eye on and we have a breakdown of all the biggest ones to watch on Friday!



Moving stocks are mergers, clinical trial data, public offerings and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Crown LNG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGBS#NASDAQ">CGBS</a>) stock is rocketing almost 154% after <a href="https://finance.yahoo.com/news/crown-lng-holding-announces-completion-201700767.html">recently completing a business combination</a>.</li>



<li>Toyo (NASDAQ:<a href="https://investorplace.com/stock-quotes/toyo-stock-quote/">TOYO</a>) shares are soaring close to 111% alongside heavy pre-market trading.</li>



<li>Sentage (NASDAQ:<a href="https://investorplace.com/stock-quotes/sntg-stock-quote/">SNTG</a>) stock is surging over 60% with strong early morning trading.</li>



<li>Above Food Ingredients (NASDAQ:<a href="https://investorplace.com/stock-quotes/abve-stock-quote/">ABVE</a>) shares are increasing more than 42% without any clear news this morning.</li>



<li>Monterey Capital Acquisition (NASDAQ:<a href="https://investorplace.com/stock-quotes/mcac-stock-quote/">MCAC</a>) stock is gaining over 23% on Friday morning.</li>



<li>Maxeon Solar Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/maxn-stock-quote/">MAXN</a>) shares are rising more than 19% with heavy early morning trading.</li>



<li>Qualigen Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/qlgn-stock-quote/">QLGN</a>) stock is heading nearly 16% higher with strong pre-market trading.</li>



<li>Immutep (NASDAQ:<a href="https://investorplace.com/stock-quotes/immp-stock-quote/">IMMP</a>) shares are climbing over 15% with <a href="https://www.nasdaq.com/market-activity/stocks/immp/press-releases">positive clinical results</a>.</li>



<li>Big Tree Cloud (NASDAQ:<a href="https://investorplace.com/stock-quotes/dsy-stock-quote/">DSY</a>) stock is jumping more than 14% on Friday.</li>



<li>Instil Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/til-stock-quote/">TIL</a>) shares are up over 14% today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Shineco (NASDAQ:<a href="https://investorplace.com/stock-quotes/sisi-stock-quote/">SISI</a>) stock is crashing more than 44% on a <a href="https://www.nasdaq.com/press-release/shineco-announces-proposed-underwritten-public-offering-2024-07-11">proposed public offering</a>.</li>



<li>ASP Isotopes (NASDAQ:<a href="https://investorplace.com/stock-quotes/aspi-stock-quote/">ASPI</a>) shares are diving over 19% as it also announces a <a href="https://www.globenewswire.com/news-release/2024/07/11/2912107/0/en/ASP-Isotopes-Announces-Proposed-Public-Offering-of-Common-Stock.html">proposed public offering</a>.</li>



<li>Cyngn (NASDAQ:<a href="https://investorplace.com/stock-quotes/cyn-stock-quote/">CYN</a>) stock is tumbling 18% following a <a href="https://www.nasdaq.com/press-release/more-1bn-annual-sales-alta-equipment-group-joins-cyngns-dealer-network-2024-07-11">massive rally yesterday</a>.</li>



<li>Kazia Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/kzia-stock-quote/">KZIA</a>) shares are retreating more than 16% <a href="https://investorplace.com/2024/07/kzia-stock-alert-kazia-continues-its-surge-on-thursday-with-51-gains/">after rallying this week</a>.</li>



<li>Nano Nuclear Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/nne-stock-quote/">NNE</a>) stock is taking an over 12% beating after <a href="https://www.nasdaq.com/press-release/nano-nuclear-energy-announces-pricing-upsized-18-million-underwritten-offering-2024">pricing an upsized underwritten offering</a>.</li>



<li>Biodexa Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/bdrx-stock-quote/">BDRX</a>) shares are falling more than 10% after jumping yesterday on <a href="https://seekingalpha.com/news/4123698-biodexa-stock-rallies-amid-release-of-phase-2-data-for-erapa">clinical trial data</a>.</li>



<li>Digital Brands Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/dbgi-stock-quote/">DBGI</a>) stock is dropping over 10% this morning.</li>



<li>Sonoma Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/snoa-stock-quote/">SNOA</a>) shares are decreasing more than 10% following a Thursday rally.</li>



<li>Forward Industries (NASDAQ:<a href="https://investorplace.com/stock-quotes/ford-stock-quote/">FORD</a>) stock is dipping 10% without any news to report.</li>



<li>Nuwellis (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuwe-stock-quote/">NUWE</a>) shares close out our pre-market stock movers down over 9% this morning.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-july-12th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Shineco stock slides after pricing stock offering to raise $2 million

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Shineco&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/sisi-stock-quote/">SISI</a>) stock is falling hard on Friday after the agricultural produce company announced the <a href="https://finance.yahoo.com/news/shineco-announces-pricing-2-million-120000343.html">pricing of a public offering</a> for its shares.



This public offering has Shineco selling 1,869,160 shares of SISI stock for $1.07 each. The offering also includes a 45-day option for underwriters to acquire another 280,374 shares at the public offering price.



Shineco is expecting $2 million in gross proceeds from this public offering. The sole book-running manager for the offering is EF Hutton LLC.



<h2>How This Affects SISI Stock</h2>



A public offering increases the total number of outstanding shares on the market. Doing so also dilutes the stakes of current investors in the company. This is one of the reasons why shares of SISI stock are falling today.



On top of that, traders likely aren&rsquo;t happy about the $1.07 price for shares in the offering. That&rsquo;s below the prior closing price of $2.12 per share for SISI stock. It makes sense the stock would fall alongside this discounted public offering price.



SISI stock is down 53.8% as of Friday morning. However, the shares were up 76.7% year-to-date when markets closed on Thursday.



Investors who are seeking out even more of the most recent stock market stories will want to stick around!



We have all of the hottest stock market news that traders need to know about on Friday! A few examples include what&rsquo;s going on with shares of Toyo&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/toyo-stock-quote/">TOYO</a>) and Crown LNG&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/cgbs-stock-quote/">CGBS</a>)&nbsp;stock, as well as the biggest pre-market movers this morning. All of this info is ready at the following links!



<h2>More Friday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/07/why-is-toyo-toyo-stock-up-119-today/">Why Is Toyo (TOYO) Stock Up 119% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/why-is-crown-lng-cgbs-stock-up-65-today/">Why Is Crown LNG (CGBS) Stock Up 65% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-july-12th/">Today&rsquo;s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on&nbsp;Friday</a></li>
</ul>On Penny Stocks and Low-Volume Stocks:&#8239;With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>



On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/why-is-shineco-sisi-stock-down-54-today/">Why Is Shineco (SISI) Stock Down 54% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Shineco (SISI) Stock Down 54% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
ASP Isotopes&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/aspi-stock-quote/">ASPI</a>) stock is down on Friday after the development stage advanced materials company <a href="https://finance.yahoo.com/news/asp-isotopes-announces-proposed-public-200100923.html">announced a proposed public offering</a> for its shares.



The company hasn&rsquo;t revealed the finer details of this offering just yet. That means we don&rsquo;t know how many shares it will include or what they will be priced at. We also don&rsquo;t know how much it expects to raise from the offering.



What he do know is that ASP Isotopes intends to offer an additional 15% of shares in the offering to underwriters. This will give sole bookrunner Canaccord Genuity 30 days after the offering to acquire ASPI shares at the offering price.



<h2>What This Means for ASPI Stock</h2>



A public offering will increase the total number of ASPI shares on the public market. Doing this will also dilute the stakes of investors in the company. This is one of the reasons why the stock is falling on Friday.



Additionally, the shares in the public offering are likely to be discounted from the stock&rsquo;s prior closing price. This has investors anticipating that discount, which helps explain why the stock is down when the price hasn&rsquo;t been announced yet.



ASPI stock is down 19.4% as of Friday morning. The shares are up 104.6% since the start of the year.



Investors will want to keep reading for more of the most recent stock market stories!



We have all of the hottest stock market news traders need to know about on Friday! That includes what&rsquo;s going on with Shineco&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/sisi-stock-quote/">SISI</a>) stock, Toyo&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/toyo-stock-quote/">TOYO</a>) shares and Crown LNG&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/cgbs-stock-quote/">CGBS</a>) stock this morning. All of that news is ready at the links below!



<h2>More Stock Market News for Friday</h2>



<ul><li><a href="https://investorplace.com/2024/07/why-is-shineco-sisi-stock-down-54-today/">Why Is Shineco (SISI) Stock Down 54% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/why-is-toyo-toyo-stock-up-119-today/">Why Is Toyo (TOYO) Stock Up 119% Today?</a></li>



<li><a href="https://investorplace.com/2024/07/why-is-crown-lng-cgbs-stock-up-65-today/">Why Is Crown LNG (CGBS) Stock Up 65% Today?</a></li>
</ul>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/why-is-asp-isotopes-aspi-stock-down-19-today/">Why Is ASP Isotopes (ASPI) Stock Down 19% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is ASP Isotopes (ASPI) Stock Down 19% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into the biggest pre-market stock movers as we check out all of the latest news worth reading about on Tuesday morning!



Moving stocks are new agreements, a patent, a public offering and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>SILO Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/silo-stock-quote/">SILO</a>) stock is rocketing more than 69% after <a href="https://www.nasdaq.com/press-release/silo-pharma-secures-exclusive-global-license-alzheimers-therapeutic-2024-07-16">securing a new license</a>.</li>



<li>Conduit Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/cdt-stock-quote/">CDT</a>) shares are soaring over 65% with heavy pre-market trading.</li>



<li>SciSparc (NASDAQ:<a href="https://investorplace.com/stock-quotes/sprc-stock-quote/">SPRC</a>) stock is surging more than 39% on a <a href="https://www.nasdaq.com/press-release/scisparc-announces-us-patent-application-treating-metabolic-syndrome-and-weight-loss">new weight loss patent</a>.</li>



<li>Meiwu Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/wnw-stock-quote/">WNW</a>) shares are rising over 30% with strong early morning trading.</li>



<li>Singing Machine (NASDAQ:<a href="https://investorplace.com/stock-quotes/mics-stock-quote/">MICS</a>) stock is increasing more than 25% on a <a href="https://www.nasdaq.com/press-release/singing-machines-subsidiary-semicab-announces-over-9-million-contracted-revenue">$9 million revenue backlog contract</a>.</li>



<li>Passage Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/pasg-stock-quote/">PASG</a>) shares are gaining over 18% on <a href="https://www.nasdaq.com/press-release/passage-bio-announces-positive-feedback-fda-expansion-uplift-d-trial-pbft02-include">clinical trial expansion feedback</a>.</li>



<li>AEON Biopharma (NYSEMKT:<a href="https://investorplace.com/stock-quotes/aeon-stock-quote/">AEON</a>) stock is climbing more than 16% with strong pre-market trading.</li>



<li>Shineco (NASDAQ:<a href="https://investorplace.com/stock-quotes/sisi-stock-quote/">SISI</a>) shares are getting an over 12% boost after <a href="https://www.stocktitan.net/news/SISI/shineco-announces-closing-of-2-million-underwritten-public-r9iot7ulzqfp.html">closing a public offering</a>.</li>



<li>SMX (Security Matters) (NASDAQ:<a href="https://investorplace.com/stock-quotes/smx-stock-quote/">SMX</a>) stock is jumping more than 11% <a href="https://www.nasdaq.com/press-release/smx-announces-effective-date-reverse-stock-split-2024-07-11">following a reverse stock split</a>.</li>



<li>Biomerica (NASDAQ:<a href="https://investorplace.com/stock-quotes/bmra-stock-quote/">BMRA</a>) shares are up over 11% this morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Autonomix Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/amix-stock-quote/">AMIX</a>) stock is diving more than 18% <a href="https://www.nasdaq.com/press-release/autonomix-enters-definitive-agreement-license-intellectual-property-fda-cleared">following a rally yesterday</a>.</li>



<li>Vince (NYSE:<a href="https://investorplace.com/stock-quotes/vnce-stock-quote/">VNCE</a>) shares are tumbling over 17% without any clear news this morning.</li>



<li>TuanChe (NASDAQ:<a href="https://investorplace.com/stock-quotes/tc-stock-quote/">TC</a>) stock is taking a more than 17% beating on Tuesday morning.</li>



<li>Greenpro Capital (NASDAQ:<a href="https://investorplace.com/stock-quotes/grnq-stock-quote/">GRNQ</a>) shares are sliding over 17% after <a href="https://www.nasdaq.com/press-release/greenpro-capital-corp-and-green-x-corp-forms-strategic-alliance-bank-islam-trust">rising yesterday on a strategic alliance</a>.</li>



<li>Lottery.com (NASDAQ:<a href="https://investorplace.com/stock-quotes/ltry-stock-quote/">LTRY</a>) stock is dropping more than 16% on Tuesday.</li>



<li>Vicinity Motor (NASDAQ:<a href="https://investorplace.com/stock-quotes/vev-stock-quote/">VEV</a>) shares are decreasing over 16% this morning.</li>



<li>Tantech (NASDAQ:<a href="https://investorplace.com/stock-quotes/tanh-stock-quote/">TANH</a>) stock is falling more than 15% despite a lack of news this morning.</li>



<li>MF International (NASDAQ:<a href="https://investorplace.com/stock-quotes/mfi-stock-quote/">MFI</a>) shares are slipping over 14% on Tuesday morning.</li>



<li>Cyngn (NASDAQ:<a href="https://investorplace.com/stock-quotes/cyn-stock-quote/">CYN</a>) stock is dropping close to 14% <a href="https://www.benzinga.com/news/24/07/39781479/cyngn-shares-were-up-by-more-than-50-whats-going-on">after a recent rally</a>.</li>



<li>Lixiang Education (NASDAQ:<a href="https://investorplace.com/stock-quotes/lxeh-stock-quote/">LXEH</a>) shares close out our pre-market stock movers down more than 12% today.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-july-16th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Shineco ( ($SISI) ) just unveiled an announcement. The Company recently held its 2025 annual general meeting, where key proposals were approved, in...

Shineco Approves Key Proposals at 2025 AGM

19:50 EST Shineco (SISI) Inc trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving breaking fin...

Shineco Inc trading halted, news pending

Shineco (SISI) announced that effective at 12:01 a.m., EDT, on November 12, 2024, the Company will effect a one-for-twenty four reverse stock split...

Shineco announces 1-for-24 reverse stock split

The latest announcement is out from Shineco ( ($SISI) ). Shineco, Inc. has announced a 1-for-24 reverse stock split to comply with NASDAQ's listing...

Shineco Implements 1-for-24 Reverse Stock Split

An update from Shineco ( ($SISI) ) is now available. Shineco Inc. has announced the resignation of independent director Mr. Aamir Ali Quraishi, to ...

Shineco Announces New Independent Director Appointment

ABVE

AEON

AMIX

ASPI

BDRX

BMRA

CGBS

DBGI

FORD

GRNQ

IMMP

KZIA

LTRY

LXEH

MAXN

MCAC

MICS

NUWE

PASG

QLGN

SILO

SISI

SNOA

SNTG

SPRC

TANH

TOYO

VNCE

Press Releases

Shineco Enters into an Agreement with Turing Video to Jointly Develop Intelligent Health Care Products

Shineco Enters into a Letter of Intent with Meitong Technology to Address China's Aging Population

Shineco, Inc. Announces Entering into a Securities Purchase Agreement with Gross Proceeds of $7.0 Million

Shineco Regains Compliance with Nasdaq Minimum Bid Price Requirement

Shineco Announces New Distribution Agreements for over $30 Million in Sales for its New Health Food Beverage

Shineco Announces Proposed Underwritten Public Offering

Shineco Announces Pricing of $2 Million Underwritten Public Offering

Shineco Announces Closing of $2 Million Underwritten Public Offering

Fintech

Future FinTech Announces the Appointment of Hu Li as the New CEO

Shineco Announces Reverse Split to Regain NASDAQ Compliance

FTFT

AXIL Brands

Elevai Labs

Flora Growth

Mannatech

Natural Alternatives International, Inc. - Common Stock

Natural Alternatives Intl

Natural Health Trends Corp. - Commn Stock

Natural Health Trends

Paranovus Entertainment Technology Ltd. - Class A Ordinary Shares

Comments

Shineco

Noticias

Últimas noticias sobre Shineco (NASDAQ:SISI) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL